Concinnity is developing modular, multi-functional, RNA-based gene control systems that form part of the gene therapy cassette. They are inserted into the 3’ UTR and become active after transcription of the cassette to mRNA. These control systems are programmed to respond to internal or externally provided molecules and control gene expression in a defined manner by modulating the amount of gene therapy mRNA in the patient’s cells.
RNA-based control systems have a number of advantages, including no requirement for additional genetic components, their small size of <150 bp (freeing up space for the therapeutic payload) and their applicability across a broad range of therapeutics, most notably mRNA therapeutics where conventional DNA-based control systems (e.g. synthetic promoters) cannot be used.